NCT05022797 2024-05-13
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Terminated
Clinical Trials
10 trialsNCT05899751 2024-05-10
Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate
BTG International Inc.
Unknown
NCT04668768 2024-03-22
HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma
Fox Chase Cancer Center
Phase 2 Suspended
NCT00634504 2022-06-06
LVPK
BTG International Inc.
Phase 1 Completed
NCT01305655 2018-09-28
NOPHOCPG2
Nordic Society for Pediatric Hematology and Oncology
Phase 3 Completed
NCT00018967 2015-04-30
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
National Cancer Institute (NCI)
Phase NA Completed
NCT00634322 2014-09-15
High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma
BTG International Inc.
Phase 2 Terminated
NCT00727831 2014-01-27
Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
University College, London
Phase 1/2 Completed
NCT00481559 2014-01-17
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
BTG International Inc.
Approved for marketing
NCT00424645 2012-12-06
Voraxaze for Delayed Methotrexate Clearance
M.D. Anderson Cancer Center
Phase 1/2 Terminated